James Gornick - Comments
PMD Forensic Analyst with Investment Insights
Contributor's Links: Talkmarkets.com
I am a retired P.M.D. forensic analyst and I share my investment insights in economics. I am a high-powered mind with a forensic edge — part Wall Street watchdog, part biotech sleuth, part AI futurist. I chase truth like a bloodhound through economic data, FDA filings, and GPU benchmarks. I’ve ...more
Latest Comments
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
3 months ago
Thank you for your great surprise in the thoroughness I tend to take when writing but especially research put in before the ink even hits the paper.
In this article: CYDY
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
3 months ago
Hey Doc, Thanks for the warm response to this article. Here’s the quick summary from what I thought they achieved: In short, the critical takeaway from CytoDyn’s ESMO showing is that the company delivered—for the first time—a coherent mechanistic explanation (PD-L1 induction via CCR5 blockade) that dovetails with its extraordinary long-term survival anecdotes. This elevates leronlimab from an interesting case series to a candidate with a testable, potentially platform-wide value proposition in solid-tumor oncology. I think I write a follow up article on this one because it was significant enough to raise CytoDyn on one of those Penny Stocks that you turn your head over a few months or weeks pending their meetings with the FDA, they become a $7.75 to $12.35 a share because of them being so diluted with the amount of shares they have issued to date. Hope this helps a little bit in bringing some clarity from my view point.
In this article: CYDY
Building Wealth Through Economics: A Patriotic Investor’s Guide To Tariffs 2.0 And Why
3 months ago
Thank you, Adam. I was on vacation from all electronics for the past three weeks. I am getting around to catching up.
In this article: MSLR, CAT, CMA, CVX, GM, LLY, JPM, LMT, NUE, PFE, XOM
Implications Of New FDA Leadership In The Biotechnology Industry
4 months ago
I believe those deaths aren’t on RFK Jr., mostly if you rip apart the CDC and the actual command center at HHS, they aren’t messing around whatsoever with the Measles as the vaccines have been 100 % available to every single child, infant, or adult who requested themselves or their loved one’s to be vaccinated. Separate, but just as important, the push by HHS is to not turn anyone away and treating everyone who enters a hospital. Where are you gathering the support for your accusations? Just wondering! It’s important to remember that someone’s personal opinion, even though he would have a history as you tried to point towards, doesn’t in any way shape what’ he’s been involved with to date or has accomplished. Just saying! I appreciate your opinion and not here to make Talkmarkets.com a venue for making statements other than what you could clearly gather from the entire article based on many sources and knowledge held by this writer.
Implications Of New FDA Leadership In The Biotechnology Industry
4 months ago
I would say if all the departments under RFK Jr. do what they were mandated to do, I would certainly expect the Americans will become healthier again. Not to mention all the sweeping reforms to clean up many problematic areas found by DOGE.
Implications Of New FDA Leadership In The Biotechnology Industry
4 months ago
This area we named UGLY puts in right context why RFK Jr. along with the complete HHS directors must play by this Higher Gold Standard and stay focused on not allowing the political sides or own interests ever come into the entire operations of each department under RFK Jr. tenure. Thanks for reading through the article.
Building Wealth Through Economics: A Patriotic Investor’s Guide To Tariffs 2.0 And Why
4 months ago
Thank you, as this article had incredible amount of layers to unwind.
In this article: MSLR, CAT, CMA, CVX, GM, LLY, JPM, LMT, NUE, PFE, XOM
Building Wealth Through Economics: A Patriotic Investor’s Guide To Tariffs 2.0 And Why
4 months ago
While your sarcasm is noted, it's important to address the substance of the argument. The article clearly outlines relevant points and has no connection to January 6. As indicated, exploring deeper issues and considering the impact of policies like Trump's Tariff 2.0 will provide more insightful discussions.
In this article: MSLR, CAT, CMA, CVX, GM, LLY, JPM, LMT, NUE, PFE, XOM
FDA Advisory Committee Shakeup And Implications For Capricor Therapeutics
5 months ago
Thank you Susan for your very kind words. Just retired from over forty years working in the emergency medical care field as a PMD. The reason for my absence from submitting articles mostly came to not want to be gathered into the social media platforms and finding how clueless many who’ve come from a negative adversary can be draining if you allow them to keep your attention on them. You will definitely be seeing some quiet in-depth articles on subjects I find either investable or needs the subject matter broken down into manageable chunks of critical content subject matter provided to those seeking viewing complex topics brought in the form of understanding the content presented. Thanks again for your thoughts and prayers as they are appreciated.
In this article: CAPR
1 to 10 of 46 comments
1 2 3 ... 5 >>>